Norah Lynn Henry, MD, PhD

Lynn Henry
Daniel F Hayes M.D. Breast Cancer Research Professor
Professor of Internal Medicine
Associate Division Chief for Clinical Research
Section Head and Assistant Director for Training, Education and Career Development (TECD) in Cancer Center
Medical School
Phone:
Available to mentor
Norah Lynn Henry, MD, PhD
Lynn Henry
Professor
  • About
  • Qualifications
  • Center Memberships
  • Recent Publications
  • Manage Your Profile

  • About

    N. Lynn Henry, MD, PhD is a Professor of Internal Medicine and Associate Director for Community Outreach and Engagement for the Rogel Cancer Center. She was formerly Interim Division Chief and section head for breast oncology in the Division of Hematology/Oncology, associate director of Training, Research, and Education for the Rogel Cancer Center, and Co-Director of the Michigan Breast Oncology Quality Consortium. She is also Co-Chair of the Symptom Management and Quality of Life Committee for the SWOG National Cancer Treatment Network research base. She completed her undergraduate training at Louisiana State University, her doctoral degree in structural biology at Stanford University School of Medicine, and her medical degree at Washington University School of Medicine in St Louis, MO. She then completed her internal medicine residency training at Brigham and Women's Hospital in Boston, MA, followed by hematology/oncology fellowship at the University of Michigan. Dr. Henry cares for patients with all types and stages of breast cancer. Her research is focused on toxicity of therapy for patients with breast cancer, including understanding the mechanisms of development of side effects, identifying which patients are likely to tolerate treatment, and examining interventions to manage toxicity. She has received grant funding from the National Cancer Institute, the American Cancer Society, the Damon Runyon Cancer Research Foundation, the V Foundation, the Hope Foundation for Cancer Research, and the Breast Cancer Research Foundation.

    Qualifications

    • Hematology/Oncology Fellowship
      University of Michigan, United States
      2004 - 2007
      Clinical Fellowship
    • Internal Medicine Residency
      Brigham and Women's Hospital, Boston, MA, United States
      2001 - 2004
      Residency
    • MD
      Washington University School of Medicine, 660 S. Euclid, St Louis, Missouri, 63110, United States
      1996 - 2001
    • PhD
      Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California, 94305, United States
      1991 - 1996

    Center Memberships

    • Center Member
      Taubman Institute
    • Center Member
      Institute for Healthcare Policy and Innovation
    • Center Member
      Rogel Cancer Center
    • Center Member
      e-Health and Artificial Intelligence Initiative
    • Center Member
      AI and Digital Health Innovation
    • Center Member
      Center for Global Health Equity

    Recent Publications

    See All Publications
    • Presentation
      Strategies to mitigate musculoskeletal symptoms using nonpharmacologic approaches
      Henry L. 2026 Aug 22;
    • Presentation
      Targeting the gut microbiome to manage arthralgia in patients treated with aromatase inhibitors
      Henry L. 2026 Aug 22;
    • Journal Article
      Comparison of five definitions of meaningful change on patient-reported outcomes in four SWOG clinical trials
      Jones SMW, Till C, Unger JM, Hershman DL, Henry NL, Berry DL, Patel S, Hall E. Journal of Patient-Reported Outcomes, 2026 Aug 19; DOI:10.1186/s41687-026-01182-2
    • Journal Article
      COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.
      Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil M, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. J Clin Oncol, 2026 Jul 29; JCO2503052 DOI:10.1200/JCO-25-03052
      PMID: 42525921
    • Journal Article
      Adverse Events in a Randomized Trial Comparing Radiotherapy with or without Olaparib for Inflammatory Breast Cancer.
      Jagsi R, Meisner A, Chalasani P, Lew D, Barlow WE, Bellon JR, Henry NL, Matuszak MM, Moran JM, Pierce LJ, Rakovitch E, Reyes SJ, Speers C, Unger JM, White JR, Woodward WA, Zellars RC, Pusztai L, Sharma P. Int J Radiat Oncol Biol Phys, 2026 Jul 28; DOI:10.1016/j.ijrobp.2026.07.029
      PMID: 42520859
    • Presentation
      Survivorship: ASCO Updates
      Henry L. 2026 Aug 8;
    • Journal Article
      Centralized Pain Diagnoses in Older Adults With and Without Cancer.
      Irwin MN, Marshall V, Henry NL, Farris K, Smith MA. J Pain Palliat Care Pharmacother, 2026 Jul 25; 1 - 11. DOI:10.1080/15360288.2026.2701348
      PMID: 42500954
    • Journal Article
      Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.
      Hamilton-Reeves JM, Unger JM, Holzbeierlein JM, Lew DL, Mark JR, Daneshmand S, Lerner SP, Kukreja JEB, Lee EK, Tabayoyong WB, Hershman DL, Fisch MJ, Henry NL. JAMA Netw Open, 2026 Aug 8; 9 (7): e2623622 - e2623622. DOI:10.1001/jamanetworkopen.2026.23622

    Featured News & Stories

    ribbons in colorful colors lined up next to eachother
    Health Lab

    5-year survival rate has increased for all cancers, according to American Cancer Society

    The American Cancer Society reports that mortality rates have continued to decline since the 1990s. N. Lynn Henry, of Michigan Medicine, answers questions about how factors such as healthy lifestyle choices, early screening and clinical trials have improved cancer survival rates.